Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758561 | 1.00 | HTR5A (0.32) | HTR5AHTR2AHTR2CBACE1 | |
| SCHEMBL25758641 | 0.87 | KMT2A (0.36) | — | |
| SCHEMBL25758557 | 0.87 | KMT2A (0.36) | — | |
| SCHEMBL25758607 | 0.81 | AKR1B1 (0.34) | HTR5AHTR2AHTR2C | |
| SCHEMBL25758519 | 0.81 | AKR1B1 (0.34) | HTR5AHTR2AHTR2C | |
| SCHEMBL23835757 | 0.80 | KMT2A (0.40) | HTR2AHTR2C | |
| SCHEMBL25758517 | 0.80 | AKR1B1 (0.35) | HTR5AHTR2AHTR2C | |
| SCHEMBL25758600 | 0.80 | AKR1B1 (0.35) | HTR5AHTR2AHTR2C | |
| SCHEMBL24019924 | 0.80 | KMT2A (0.40) | HTR2AHTR2C | |
| SCHEMBL25758652 | 0.75 | PDK2 (0.41) | HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | HTR5A 4019/4885HTR2A 3850/4885HTR2C 1468/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HTR5A 3995/4885HTR2A 3835/4885HTR2C 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.